

## Nanologica Q2 2024 - Improvement in production

Redeye maintains a positive outlook on Nanologica following its Q2 report. Production has improved and it seems that the company is poised for growth in the near term. While we mostly maintain our fair value range, we have made some adjustments to our estimates.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

## **Attachments**

Nanologica Q2 2024 - Improvement in production